HOME >> BIOLOGY >> NEWS
Researchers discover why mutant gene causes colon cancer

Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene have been found to cause 85 percent of colon cancers. Now researchers at the University of Utah's Huntsman Cancer Institute know why. In a paper published on-line Sept. 9 in the Journal of Biological Chemistry, they explain that APC controls the conversion of dietary vitamin A into retinoic acid. If this process is impaired, colon cancer can result.

"For a long time, scientists believed they knew what the APC gene did that it regulated cell growth and division but now we know we've been missing a big piece of the picture," reports David Jones, Ph.D., principal investigator of the study and leader of HCI's Colon Cancer Scientific Program. "What we didn't know was that it converts vitamin A into retinoic acid, which is vital for normal colon cell development."

Jones' lab had recently demonstrated that lack of retinoic acid, induced by mutating the APC gene, led to cancerous tumors in human colon cell lines. The new study blocked APC function in zebrafish and demonstrated that when the APC gene was blocked, the fish embryos lacked normal intestinal lining cells. When the embryos were treated with retinoic acid, normal cell development was restored. Because zebrafish and humans share many genes, including the APC gene, researchers often use the little black-and-white striped fish as models to study various aspects of human development.

"Implications of this study are far reaching," Jones says. "We have long suspected that vitamin A was helpful in preventing certain cancers, including colon cancer. With this new understanding, it may be possible to bypass a non-functioning APC gene by introducing retinoids as a form of chemoprevention, and thus control the undifferentiated and uncontrolled growth of colon cells that results in colon cancer."

Several years ago, University of Utah researchers identified the APC gene, as well as an inherited colon ca
'"/>


9-Sep-2004


Page: 1 2

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers identify the genomes controlling elements
11. Researchers improve detection of diverse anthrax strains

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... 05, 2020 , ... Regenative Labs has received approval from the Centers for ... them the first Wharton’s jelly allografts to be assigned a Q code and be ... the first Wharton’s jelly allograft product to be recognized as a 361 HCT/P by ...
(Date:7/18/2020)... ... July 16, 2020 , ... ... effectiveness of the Invictus Medical Neoasis™ active noise control device to attenuate typical ... that the Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators and ...
(Date:7/2/2020)... ... 01, 2020 , ... AltruBio Inc. http://www.altrubio.com , a ... for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European Hematology Association ... of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase 1 single ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... 2020 , ... Medial EarlySign , a leader in ... high-burden diseases, and Centric Consulting, a business and technology consulting firm, today announced ... in order to identify and prioritize patients for care. , Combining Centric’s management ...
(Date:7/10/2020)... ... 09, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology ... R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will ... SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine at the ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... the launch of a new clinical diagnostics immuno-oncology service, TissueInsight . ... (TME). , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, and ...
(Date:6/23/2020)... ... June 23, 2020 , ... Kerafast Inc. , developers ... announced the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The ... of SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 ...
Breaking Biology Technology:
Cached News: